Uyanik, Mehmet SevkiBaysal, MehmetPamuk, Gulsum EmelMaden, MuhammetAkker, MustafaUmit, Elif GulsumDemir, Muzaffer2024-06-122024-06-1220160971-45020974-0449https://doi.org/10.1007/s12288-015-0578-2https://hdl.handle.net/20.500.14551/19807The most common genetic disorder in Philadelphia negative chronic myeloproliferative neoplasms is the JAK2-V617F mutation. In the present study, we aimed to determine risk factors for thrombosis in patients with essential thrombocytosis and polycythemia vera. We screened the medical records of 101 patients. Risk factors which may predict thrombosis were recorded. Venous thrombosis (VT) before diagnosis was significantly higher in JAK2 positive patients. VT after diagnosis was similar in JAK2 positive and negative groups, and was significantly higher in elderly patients. Treatment places importance on the JAK2 mutation under unmodifiable cardiovascular risk factors such as advanced age after diagnosis.en10.1007/s12288-015-0578-2info:eu-repo/semantics/openAccessChronic Myeloproliferative NeoplasmsJAK2 MutationAllele BurdenThrombosisJak2 V617f MutationWorld-Health-OrganizationEssential ThrombocythemiaPolycythemia-VeraHigh-RiskAllele BurdenHydroxyureaDiseaseTransformationJak2(V617f)Is JAK2V617F Mutation the Only Factor for Thrombosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms?Article323262267Q4WOS:0003789942000042-s2.0-8493961163627429517Q3